This retrospective cohort study reports that taking either an angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) was not associated with an increase in the likelihood of testing positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

While overlap propensity score–weighted analysis showed a higher likelihood of hospital admission among patients with positive test results who were taking either ACEIs or ARBs, these data must be interpreted with caution and considered only hypothesis generating, due to the small sample size and the wide width of the confidence intervals.

A total of 18,472 patients tested for COVID-19. The mean (standard deviation) age was 49 (21) years, 7,384 (40%) were male, and 12,725 (69%) were white. Of 18,472 patients who underwent COVID-19 testing, 2,285 (12.4%) were taking either ACEIs or ARBs.

Read More